Nomura Holdings Inc. Acquires New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Nomura Holdings Inc. bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,357 shares of the company's stock, valued at approximately $459,000.

Other large investors also recently modified their holdings of the company. Braidwell LP acquired a new position in TransMedics Group during the fourth quarter valued at approximately $57,493,000. Norges Bank acquired a new position in TransMedics Group during the fourth quarter valued at approximately $22,861,000. Dimensional Fund Advisors LP increased its holdings in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. Emerald Advisers LLC raised its holdings in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after purchasing an additional 220,804 shares during the period. Finally, FIL Ltd boosted its stake in shares of TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after acquiring an additional 218,961 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Up 0.7%

TMDX traded up $0.91 during trading on Friday, hitting $124.25. 443,082 shares of the company's stock traded hands, compared to its average volume of 1,359,384. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company's 50 day simple moving average is $89.57 and its two-hundred day simple moving average is $77.29. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of 132.18 and a beta of 1.91. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group's revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.35 EPS. Analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of analyst reports. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Piper Sandler reissued an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $126.70.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 732 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now owns 12,134 shares in the company, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now directly owns 732 shares of the company's stock, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.